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1. Introduction 
Postoperative rhythm disorders are a serious complication of coronary surgery and they are 
associated with increased morbidity and mortality. Atrial fibrillation is the most common 
complication after cardiac surgery, with an incidence of 30% after coronary artery bypass 
grafting (Camm et al.,2010). There are few data about the etiology of atrial fibrillation in this 
setting, factors such as intraoperative atrial ischemia, pericarditis, and excessive adrenergic 
stimulation, were incriminated in its occurrence in vulnerable patients (Lucio et al., 2004). 
The peak incidence of postoperative atrial fibrillation is between postoperative days 2 and 4 
(Camm et al.,2010). Although frequently these arrhythmias are benign and transient, 
patients developing postoperative atrial fibrillation are more likely to have perioperative 
myocardial infarction, stroke, congestive heart failure, respiratory failure, prolonged 
hospitalization and intensive coronary unit (ICU) stay and therefore increased economic 
burden of their care (Lucio et al., 2004; Iliuta et al., 2009; Burgess et al., 2006). 
Many clinical trials and multiple meta-analyses evaluated the efficacy of pharmacological and 
non-pharmacological interventions in prevention of postoperative atrial fibrillation. The meta-
analyses and systematic reviews showed that interventions to prevent and/or treat 
postoperative atrial fibrillation with beta-blockers, sotalol, or amiodarone and, less 
convincingly, atrial pacing, are favoured with respect to outcome (atrial fibrillation occurence, 
stroke, and length of hospitalisation) (Burgess et al., 2006; Crzstal et al., 2004). Currently, 
preoperative or early postoperative administration of beta-blockers is considered a first line 
choice to prevent atrial fibrillation after coronary artery bypass grafting except in patients with 
contraindications to beta-blocker therapy (Camm et al.,2010; Eagle et al., 2004). In patients with 
conduction abnormalities, severe left ventricular dysfunction, active bronchospasm or marked 
resting bradycardia the use of beta-blockers is difficult and controversial.  
The hyperpolarization-activated pacemaker current (If) channel inhibitor ivabradine, which 
induces heart rate reduction by selective sinus node inhibition, showed improvement of 
clinical outcomes in patients with stable coronary artery disease and left ventricular systolic 
dysfunction (Fox et al., 2008) or chronic heart failure (Swedberg et al., 2010). Data regarding 
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the benefits of ivabradine used postoperatively in patients with conduction abnormalities or 
left ventricular dysfunction undergoing coronary surgery are scarce. 
The main objectives of our study were to compare the efficacy and safety of heart rate lowering 
agent ivabradine versus beta-blocker metoprolol used perioperatively in patients undergoing 
coronary artery bypass grafting and having conduction abnormalities (first degree 
atrioventricular block or bundle branch block) or left ventricular dysfunction and also to 
determine whether prophylactic therapy with ivabradine can reduce hospital stay and economic 
costs after cardiac surgery by lowering the risk associated with an increased heart rate. 
2. Methods 
This trial was an open-label, randomized, clinical trial which enrolled 315 patients 
undergoing coronary artery bypass grafting with arteries (internal mammary, radial, 
gastroepiploic) or inverted saphenous veins in a single center (Cardiac Surgery Department 
of “Prof. Dr. C. C. Iliescu” Emergency Institute of Cardiovascular Diseases, Bucharest, 
Romania) between January 1st, 2006 and December 31st, 2007. Surgical management and 
treatment of the patients were based on a common standard protocol. 
2.1 Eligibility criteria 
Patients included in the clinical trial were patients undergoing elective coronary artery 
bypass grafting who had conduction abnormalities, left ventricular systolic dysfunction or 
both.  
2.2 Exclusion criteria 
Patients non-eligible for the study were patients exhibiting one or more of the following 
conditions: 
1. second and third degree atrioventricular block 
2. bradycardia (heart rate less than 50 beats per minute) or conditions associated with 
increased risk for bradycardia (vagal predominance, sick sinus syndrome) 
3. NYHA class IV heart failure 
4. cardiogenic shock 
5. severe chronic obstructive pulmonary disease or pulmonary impairment 
6. known hypersensitivity to beta-blockers or ivabradine 
7. active participation in another clinical trial 
8. failure to comply with the hospital protocol or absence to follow-up. 
Study drop out criteria included the occurrence of adverse events: severe bradycardia, skin 
reactions, gastrointestinal symptoms, cold extremities. The study protocol was approved by 
the institute Management and Ethics Committee. All patients included in the trial gave 
written informed consent for participation in this study. 
2.3 Study groups 
After inclusion in the study, two days before surgery, patients were randomized in three 
groups: 
1. Group A: 104 patients to receive metoprolol 100 mg once daily; 
2. Group B: 106 patients to receive metoprolol 50 mg once daily and ivabradine 5 mg 
twice daily; 
3. Group C: 105 patients to receive ivabradine 5 mg twice daily. 
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The treatment phase comprised 2 days preoperatively and at least 10 days postoperatively 
and the patients were followed-up for 30 days after surgery (Fig. 1). 
 
 
Fig. 1. Study phases and distribution of study population 
2.4 Clinical and laboratory assessments 
Patients were evaluated at baseline (ie. 2 days before surgery), daily from Day 1 until Day 10 
postoperatively, on Day 15, and at the end of the treatment on Day 30 postoperatively. 
Patients with short in-hospital evolution were evaluated ambulatory. 
Clinical parameters included NHYA class, ventricular rhythm, patient compliance, and 
quality of life.  
Laboratory parameters assessed were: usual blood tests (white and red blood cell count, 
platelet count, hemoglobin, hematocrit, alanine aminotransferase and aspartate 
aminotransferase, lactate dehydrogenase, blood chemistry), electrocardiogram (ECG) (with 
the evaluation of rhythm and rate), 24-h ECG Holter monitoring and echocardiographic 
measurements of the left ventricular dimensions, left ventricular systolic and diastolic 
performance, left atrium dimensions and compliance (data not shown in the present report). 
Cardiac rhythm was continuously monitored in the intensive care unit. During further 
hospital stay, subsequent ECG tests and a 24-h ECG Holter monitoring was carried out prior 
to discharge. 
Follow-up visits were in Day 15 and in Day 30 postoperatively and included a physical 
examination and a 15-minutes interview, a resting ECG, an echocardiogram and a 24-h ECG 
Holter monitoring. Early episodes of heart failure were diagnosed based on clinical signs 
and symptoms and by transthoracic and transesophageal echocardiography. The presence 
of bradycardia or second or third degree atrioventricular block was assessed using clinical 
examination, resting ECG and 24-h ECG Holter monitoring.  
2.5 Study endpoints  
The efficacy endpoints were 30-days mortality, in-hospital occurrence of atrial 
fibrillation/arrhythmias, in-hospital occurrence of third degree atrioventricular block and 
need for pacing, in-hospital worsening heart failure and duration of hospitalization and 
immobilization. Safety endpoints were occurrence of bradycardia, gastrointestinal 
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complaints, sleep disturbances, and cold extremities. A composite efficacy and safety 
endpoint including 30-days mortality, in-hospital atrial fibrillation/arrhythmias, in-hospital 
atrioventricular block/need for pacing, or in-hospital heart failure worsening was also 
defined. 
2.6 Statistical analyses 
No sample size assumptions have been made for this trial. Continuous variable are 
presented as mean ± standard deviation (SD). Categorical variables are displayed as 
percentages. To analyze the differences between the treatment groups, the Student t test was 
used for the continuous variables and the chi-square test for the categorical variables For 
each endpoint, a two-sided 95% confidence interval (CI) was calculated and an overall χ2-
test comparing the two treatment groups was used. Also, we performed simple and 
multivariate, linear and logistic regression analysis and we calculated relative risks and 
correlation coefficients. For the primary endpoints Kaplan–Meier curves were constructed 
and log-rank tests were used. All statistical analyses were performed using SYSTAT and 
SPSS software. A p value <0.05 defined the statistical significance.  
3. Results  
In the entire study population (315 patients), mean age was 62 ± 8 years, and 65.7% of 
patients were males. Baseline demographics and clinical characteristics of the three 
treatment groups are displayed in Table 1. There were no differences in age and gender of 
patients, presence of left ventricular dysfunction or conduction abnormalities between study 
groups, systolic blood pressure or mean baseline heart rate. Also, there were no differences 
between groups in mean number of grafts/patient and grafts type, risk score for atrial 
arrhythmias and mean duration of treatment. 
The percentages of patients with previous episodes of atrial fibrillation were similar in the 
three groups (18.3% in group A, 19.8% in group B, and 19.1% in group C). There were 
similar proportions of patients with left ventricular dysfunction and conduction 
abnormalities (first degree atrioventricular block, complete left bundle branch block, 
bifascicular and trifascicular block) in the three treatment groups. 
The primary efficacy and safety, single and composite endpoints in the treatment groups are 
shown in Table 2. In-hospital postoperative atrial fibrillation or tachyarrhythmias occurred 
less frequently with combined therapy (metoprolol and ivabradine) than with metoprolol or 
ivabradine alone used in the postoperative management of patients with coronary artery 
bypass grafting (7.6% events in group B versus 11.5% events in group A and 17.1% events in 
group C, p <0.001). The associated relative risk showed a higher protective value for the 
occurence of postoperative atrial fibrillation in patients with coronary artery bypass grafting 
treated with combined therapy compared with metoprolol monotherapy (-2.9 vs. -1.8) (Fig. 
2). 
In group C the frequency of early postoperative third degree atrioventricular block or need 
for pacing was lower (2.9%) than in group A (13.5%) and in group B (9.4%) (p <0.0001). The 
frequency of heart failure worsening was lower in patients treated with ivabradine only 
(1.9%) or ivabradine combined with metoprolol (6.6%) than in patients receiving only 
metoprolol (11.5%) (p <0.001) (Table 2). The associated relative risks for early postoperative 
complete atrioventricular block or need for permanent pacing and for postoperative heart 
failure worsening were lower in ivabradine-treated groups (Fig. 2). 
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Characteristic 
Group A 
N = 104 
Group B 
N = 106 
Group C 
N = 105 
Age (years) 63 (12) 63 (12) 63 (13) 
% female 32.7% 35.9% 34.3% 
Weight (kg) 75 (15) 76 (13) 77(14) 
Height (cm) 172 (9) 170 (11) 171 (10) 
Heart rate/24h 78 (15) 76 (16) 77 (14) 
Left ventricular dysfunction 43.3% 43.4% 41.9% 
Conduction abnormalities 46.2% 47.2% 46.7% 
Systolic blood pressure (mmHg) 152 (22) 150 (28) 153 (23) 
Previous episodes of atrial arrhythmias 18.3% 19.8% 19.1% 
Hypertension 62.5% 66.0% 64.8% 
Diabetes mellitus 28.9% 33.1% 30.5% 
Re-intervention (previous coronary artery 
bypass grafting) 
10.6% 12.3% 11.4% 
Note. Parameters are expressed as mean values (standard deviation) or percentages. All p values for 
comparisons between groups were non-significant. 
Table 1. Baseline demographics and clinical characteristics of study population by treatment 
group 
 
Endpoint 
Group A 
N = 104 
Group B 
N = 106 
Group C 
N = 105 
30-day mortality, in-hospital atrial 
fibrillation/arrhythmias 
16 (15.4%) 11 (10.4%) 22 (21.0%) 
30-day mortality, in-hospital atrial 
fibrillation/arrhythmias, in-hospital 
atrioventricular block/need for pacing, or in-
hospital heart failure worsening 
42 (40.4%) 28 (26.4%) 27 (25.7%) 
Death at 30 days 4 (3.8%) 3 (2.8%) 4 (3.8%) 
In-hospital atrial fibrillation/arrhythmias 12 (11.5%) 8 (7.6%) 18 (17.1%) 
In-hospital 3 degree atrioventricular block/need 
for pacing 
14 (13.5%) 10 (9.4%) 3 (2.9%) 
In-hospital heart failure worsening 12 (11.5%) 7 (6.6%) 2 (1.9%) 
Hospitalization duration >15 days 12 (11.5%) 10 (9.4%) 9 (8.6%) 
Immobilization for >3 days 10 (9.6%) 7 (6.6%) 7 (6.7%) 
Sleep disturbances/ gastrointestinal symptoms/ 
skin reactions 
3 (2.9%) 3 (2.8%) 3 (2.9%) 
Table 2. Composite and single efficacy and safety endpoints by treatment group 
The rates of 30-day mortality were lower in the combined therapy group (2.8%) versus 
metoprolol or ivabradine monotherapy groups (3.8% in each monotherapy group). 
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Note. AV, atrioventricular. 
Fig. 2. The relative risks of ivabradine and combined therapy with ivabradine and 
metoprolol versus metoprolol monotherapy for early postoperative atrial fibrillation, 
complete atrioventricular block/need for pacing and postoperative heart failure worsening. 
The overall quality of life was better in ivabradine groups. Ivabradine-treated patients had 
shortened hospital stay (the mean duration of hospital stay in the group A was 10.2 ± 6.3 
days, compared to 8.5 ± 6.8 days in group B and 8.2 ± 6.4 days in group C), and reduced 
immobilization duration in the immediate postoperative period (2.0 ± 3 days in group A, 1.1 
± 3 days in group B and 1.1 ± 3 days in group C) (Table 2).  
The cumulative incidence of non-cardiac side effects (sleep disturbances, gastrointestinal 
symptoms, and skin reactions) was similar in ivabradine (2.9%), metoprolol (2.9%) or 
combined ivabradine or metoprolol therapy (2.8%) groups (Table 2). 
For the composite efficacy endpoint of 30-day mortality and in-hospital atrial 
fibrillation/arrhythmias the rates were 10.4% in the combined therapy group, 15.4% in the 
metoprolol group and 21.0% in the ivabradine monotherapy group. For the composite 
efficacy and safety endpoint of 30-day mortality, in-hospital atrial fibrillation/arrhythmias, 
in-hospital atrioventricular block/need for pacing, or in-hospital heart failure worsening, 
the rates were 25.7% in the ivabradine group, 26.4% in the ivabradine plus metoprolol group 
and 40.4% in the metoprolol group respectively (p = 0.0002) (Table 2), thus showing 
ivabradine therapy was superior to metoprolol therapy in terms of these composite 
endopoints. Kaplan Meier curves generated for primary endpoints also showed the superior 
efficacy and safety in ivabradine groups, either ivabradine monotherapy or combined 
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ivabradine and metoprolol therapy (Fig. 3). Log-rank tests were highly significant from 
Days 4-5 of treatment period to Day 30. 
 
 
Note. AVB, atrioventricular block, HF, heart failure. 
Fig. 3. Kaplan-Meier curves for the composite endpoint of 30-days mortality, in-hospital 
atrial fibrillation/arrhythmias, in-hospital atrioventricular block/need for pacing, or in-
hospital heart failure worsening in the three treatment groups: ivabradine alone versus 
combined ivabradine plus metoprolol and metoprolol alone 
The associated relative risks for the composite efficacy and safety endpoint of 30-day 
mortality, in-hospital atrial fibrillation/arrhythmias, in-hospital atrioventricular block/need 
for pacing, or in-hospital heart failure worsening in ivabradine-treated groups (with or 
without metoprolol) versus metoprolol-treated group in a subgroups analysis according to 
age, preoperative conduction abnormalities, NYHA class, previous episodes of atrial 
fibrillation and grafts number and type are shown in Table 3 and illustrated in Fig. 4. 
Ivabradine therapy (alone or associated to metoprolol) remained superior to metoprolol 
therapy in terms of the composite efficacy and safety endpoint of of 30-day mortality, in-
hospital atrial fibrillation/arrhythmias, in-hospital atrioventricular block/need for pacing, 
or in-hospital heart failure worsening. 
4. Discussion 
The present study is, to the best of our knowledge, the first study which evaluated the use of 
ivabradine for prevention of postoperative atrial fibrillation or other tachyarrhythmias in 
patients undergoing coronary artery bypass surgery and assessed the efficacy and safety of 
ivabradine therapy in this setting. Atrial fibrillation is the most common complication which 
occurs after cardiac surgery, with frequencies ranging from 30% after coronary artery 
bypass grafting, 40% after valve surgery, and 50% after combined coronary artery bypass 
grafting/valve surgery (Camm et al., 2010). Development of atrial fibrillation immediately 
after coronary artery bypass grafting results in longer intensive care unit and hospital stays 
(Villareal et al., 2004; Tamis & Steinberg, 2000), and a significantly higher (two- to three-fold) 
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Composite endpoint of 30-days mortality, 
in-hospital atrial fibrillation/arrhythmias, 
in-hospital atrioventricular block/need for 
pacing, or in-hospital heart failure 
worsening 
Relative risk 
metoprolol group 
N = 104 
Relative risk 
ivabradine groups 
(with or without 
metoprolol) 
N = 211 
Age 
≤70 years 
>70 years 
 
1.5 
7.8 
 
1.5 
4.9 
Previous episodes of atrial fibrillation 7.9 5.3 
Preoperative conduction abnormalities 8.2 6.3 
NYHA class 
NYHA I-II 
NYHA III-IV 
 
1.5 
8.7 
 
1.2 
5.7 
Number of grafts 
≥3 grafts 
2 grafts 
1 graft 
 
3.9 
1.3 
1.2 
 
2.5 
1.2 
1.1 
Graft type 
Exclusively arterial 
Exclusively venous 
Combined venous and arterial 
 
6.2 
6.7 
6.3 
 
3.8 
3.8 
3.3 
Table 3. Relative risks for the composite efficacy and safety endpoint of 30-days mortality, 
in-hospital atrial fibrillation/arrhythmias, in-hospital atrioventricular block/need for 
pacing, or in-hospital heart failure worsening in metoprolol versus ivabradine-treated 
patients 
risk of postoperative stroke (Villareal et al., 2004; Reed et al., 1988). Post-operative atrial 
fibrillation has also been shown to independently predict post-operative delirium and 
neurocognitive decline (Burgess et al., 2006). Patients at risk for postoperative atrial 
fibrillation have been identified and include those with chronic obstructive pulmonary 
disease, proximal right coronary artery disease, prolonged cross-clamp time, atrial ischemia, 
advanced age, and withdrawal of beta-blockers (Eagle et al., 2004). Withdrawal of beta-
blockers before surgery is a significant risk factor for the development of postoperative atrial 
fibrillation and should be avoided (Camm et al., 2010). 
Because of the increased morbidity and mortality risk and of longer hospitalisations (up to 
five days [Eagle et al., 2004]) associated with the development of atrial fibrillation during the 
immediate postoperative period and because of the economic burden of these outcomes, 
prevention of postoperative atrial fibrillation becomes increasingly important. Various meta-
analyses and systematic reviews assessed and identified pharmacologic and non-
pharmacologic intervention to best prevent and treat postoperative atrial fibrillation.  
At present, beta-blockers are the mainstay of therapy for prevention of postoperative atrial 
fibrillation in cardiac surgery. Both the ACC/AHA 2004 Guideline update for coronary 
artery bypass graft surgery for and the most recent ESC Guidelines for the management of 
atrial fibrillation recommend beta-blocker therapy as a class I indication in the prophylactic 
management of postoperative atrial fibrillation in patients without contraindications to beta-
blocker therapy (Camm et al., 2010; Eagle et al., 2004). Studies showed that withdrawal of 
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Fig. 4. Relative risks for the composite efficacy and safety endpoint of 30-days mortality, in-
hospital atrial fibrillation/arrhythmias, in-hospital atrioventricular block/need for pacing, 
or in-hospital heart failure worsening in metoprolol versus ivabradine-treated patients in a 
subgroup analysis according to age, preoperative conduction abnormalities, NYHA class, 
previous episodes of atrial fibrillation and grafts number and type. 
beta-blockers in the perioperative period doubles the incidence of postoperative atrial 
fibrillation after coronary artery bypass grafting (Eagle et al., 2004). Virtually every study of 
beta-blockers administered for the purpose of reducing postoperative atrial fibrillation has 
shown benefit in this regard, even if data regarding improvement of hospital stay or 
reduction of stroke incidence are still controversial (Iliuta et al., 2009). Most beta-blockers 
trials have examined the initiation of prophylaxis in the postoperative period. But it seems 
to be an even greater benefit if beta-blocker therapy is initiated before surgery. That is why 
the ESC guidelines for the management of atrial fibrillation recommend that treatment 
should be started at least 1 week before surgery with a beta1-blocker without intrinsic 
sympathomimetic activity (Camm et al., 2010). The beta-blockers used in studies assessing 
atrial fibrillation prevention in cardiac surgery were propranolol (Matangyi et al., 1985), 
atenolol (Lamb et al., 1988), metoprolol (Lucio et al., 2004; Crystal et al., 2004; Kamei et al., 
2006; Celik et al., 2009), acebutolol (Daudon et al., 1986), timolol (White et al., 1984), 
carvedilol (Kamei et al., 2006; Celik et al., 2009), betaxolol (Iliuta et al., 2009), either 
compared to control or to another beta-blocker. 
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Another antiarrhythmic agent used for the prevention of atrial fibrillation in cardiac surgery 
patients is sotalol which was shown to reduce the incidence of postoperative atrial 
fibrillation (Burgess et al., 2006; Crystal et al., 2004) compared to placebo or to other beta-
blocker such as atenolol (Sanjuan et al., 2004), metoprolol (Parikka et al., 1998) or 
propranolol (Suttorp et al., 1990) but it had no impact on length of hospital stay, risk of 
strokes, or mortality (Crystal et al., 2004). However, the use of sotalol in postoperative atrial 
fibrillation is limited because of its significant side effects such as bradycardia and torsade 
de pointes, especially in patients with electrolyte disturbances. For these reasons, sotalol 
therapy for atrial fibrillation prevention in cardiac surgery patients is a class IIb indication in 
the ESC Guidelines for the management of atrial fibrillation (Camm et al., 2010).  
Amiodarone and its beneficial effect in postoperative atrial fibrillation prevention was the 
subject of various studies and meta-analyses. Amiodarone decreased the incidence of 
postoperative atrial fibrillation (Burgess et al., 2006; Bagshaw et al., 2006) and significantly 
shortened the duration of hospital stay, and reduced the incidence of stroke and 
postoperative ventricular tachyarrhythmia (Burgess et al., 2006; Bagshaw et al., 2006), but 
not postoperative mortality (Bagshaw et al., 2006). The beneficial effects of amiodarone were 
observed irrespective of patients age, type of cardiac surgery (coronary artery bypass 
grafting only or valve surgery with or without coronary artery bypass grafting), and 
preoperative beta-blocker therapy. At present, amiodarone has a class IIa indication for 
atrial fibrillation prevention in patients undergoing cardiac surgery as recommended in the 
in the ESC Guidelines for the management of atrial fibrillation (Camm et al., 2010). 
Other pharmacologic agents used in clinical study for the prevention of postoperative atrial 
fibrillation were digoxin, which was not found to be effective for atrial fibrillation 
prevention (Kowey et al., 1992) or calcium channel blockers, of which non-dihydropyridines 
significantly reduced supraventricular tachyarrhythmias in a subgroup analysis of a meta-
analysis (Wijeysundera et al., 2003). Hypomagnesaemia is an independent risk factor for 
postoperative atrial fibrillation. A meta-analysis of randomized trials showed that 
prophylactic i.v. magnesium reduced the probability of postoperative atrial fibrillation 
(Miller et al., 2005). 
From the non-pharmacologic interventions investigated for atrial fibrillation prevention in 
the postoperative setting, prophylactic atrial pacing reduced the incidence of post-operative 
atrial fibrillation regardless of the atrial pacing site or pacing algorithm used, (Burgess et al., 
2006; Crystal et al., 2004) but results are controversial.  
Despite this relative large range of prophylactic interventions for postoperative atrial 
fibrillation, there are subgroups of patients with conditions that limit the use of beta-
blockers or other antiarrhythmic drugs. Among such conditions are cardiac conduction 
abnormalities or severe left ventricular dysfunction, active bronchospasm. In these patients 
ivabradine, a selective sinus node inhibitor, could be a viable alternative. Ivabradine is a 
specific inhibitor of the If current in the sinoatrial node. Consequently, it is a pure heart-rate-
lowering agent in patients with sinus rhythm, without affecting blood pressure, myocardial 
contractility, intracardiac conduction, or ventricular repolarisation. 
In BEAUTIFUL study, performed in patients with coronary artery disease and left 
ventricular systolic dysfunction (left ventricular ejection fraction of less than 40%), even if 
ivabradine failed to change the primary composite endpoint of cardiovascular death, 
admission to hospital for acute myocardial infarction, or admission to hospital for new-
onset or worsening heart failure in any of the subgroups analysed, in a subgroup of patients 
with baseline heart rate of 70 bpm or higher it reduced the incidence of endpoints related to 
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coronary artery disease (admission to hospital for fatal and non-fatal acute myocardial 
infarction) (Fox et al., 2008). Therefore, ivabradine can be used safely to patients with 
coronary artery disease and impaired left-ventricular systolic function, in conjunction with 
beta-blockers. Furthermore, a combination of ivabradine with β blockade also improved 
coronary artery disease outcomes in patients with heart rates of 70 bpm or more (Fox et al., 
2008). These results suggest that further lowering of heart rate has beneficial effects on 
coronary disease outcomes.  
In SHIFT study, performed in patients with stable symptomatic chronic heart failure and a 
left ventricular ejection fraction of 35% or lower, with a resting heart rate of 70 bpm or 
higher, ivabradine substantially and significantly reduced major risks associated with heart 
failure when added to optimal standard treatment: cardiovascular death or hospital 
admission for worsening heart failure (Swedberg et al., 2010). 
The results of these two studies supporting the importance of heart rate reduction with 
ivabradine for improvement of clinical outcomes in heart failure or coronary artery disease 
with systolic left ventricular dysfunction were the rationale for using ivabradine alone or in 
combination with metoprolol for prevention of postoperative atrial fibrillation and 
reduction of subsequent morbidity, mortality and associated economic costs in patients 
undergoing coronary artery bypass grafting. 
In our study, heart rate reduction and prevention of postoperative atrial fibrillation or 
tachyarrhythmias in the combined therapy group (ivabradine and metoprolol) was proven 
to be more effective than with metoprolol or ivabradine alone during the immediate 
postoperative management of patients undergoing coronary artery bypass grafting. 
Ivabradine-treated patients’ quality of life was improved due to shortened hospital stay, 
reduced immobilization duration in the immediate postoperative period, less atrial or 
ventricular arrhythmias, less worsening heart failure. 
Because postoperative atrial fibrillation is associated with increased morbidity and mortality 
and longer, more expensive hospital stays, we defined a composite efficacy and safety 
endpoint of 30-days mortality, in-hospital atrial fibrillation/arrhythmias, in-hospital 
atrioventricular block/need for pacing, or in-hospital heart failure worsening. Ivabradine 
and combined therapy (ivabradine and metoprolol) were superior to metoprolol in respect 
to the composite efficacy and safety endpoints for prevention of atrial fibrillation after 
coronary artery bypass grafting. 
4.1 Study limitations 
One limitation of our study is the absence of an washout period. About 85% of patients had 
preoperative beta-blocker therapy and it was not stopped before the randomization. The 
practice in our department was to routinely continue preoperative beta-blocker therapy 
without any pause and changing the active principle according to the study group. Another 
limitation is the fact that about 30% of the patients with previous episodes of atrial 
fibrillation received prior to the inclusion in the study an antiarrhythmic agent such as 
amiodarone or sotalol. These limitations would induce a possible underestimation of some 
results. 
5. Conclusion  
In patients treated with ivabradine the quality of life was improved due to shorter hospital 
stay, less atrial or ventricular arrhythmias, less need for permanent pacing, less worsening 
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heart failure, shortened immobilization during the immediate postoperative period with 
subsequent improvement in the psychological status, as well as due to lack of significant 
side effects. 
Considering the ivabradine efficacy and safety profile, the heart rate reduction in the early 
postoperative period after coronary surgery in patients with conduction abnormalities or 
left ventricular dysfunction with ivabradine therapy emerged as the best treatment in this 
trial. 
Ivabradine should be regarded as an attractive alternative pharmacological strategy for 
rhythm and heart rate control in the early postoperative period in patients undergoing 
coronary artery bypass grafting  with relative or absolute contraindications to beta-blocker 
therapy. 
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